Neurology
RSSArticles
-
Crizotinib Capsules (Xalkori®)
A new orally effective targeted therapy for the treatment of non-small cell lung cancer (NSCLC) has been approved by the FDA. Crizotinib is a receptor tyrosine kinase inhibitor including anaplastic lymphoma kinase (ALK). -
Pharmacology Watch - Full October 2011 Issue in PDF
-
Chronic medications and hospitalization
-
FDA actions
-
Chinese herbs for flu treatment
-
Apixaban trial results look promising
-
Clinical Briefs in Primary Care supplement
-
Abstract & Commentary: Patients/Surrogates Vastly Overrate Likelihood of Survival after Cardiac Arrest
Participants in this study were 100 patients/surrogates and their physicians in a 26-bed medical ICU located in an academic medical center. -
Abstract & Commentary: Low Tidal Volume Ventilation in theAbsence of Acute Lung Injury: A Study in Post-Cardiac Surgery Patients
Supported by robust data from numerous clinical trials, low-tidal-volume ventilation is now standard-of-care in managing patients with acute lung injury (ALI) or the acute respiratory distress syndrome (ARDS). -
Critical Care Alert August 2011 Issue in PDF